3D High Resolution Magnetic Resonance Fingerprinting for Prostate Cancer

项目概要 摘要 目标是使用快速方法客观、准确地识别和表征前列腺癌 定量磁共振成像（MRI）方法。患者护理标准 评估是否怀疑前列腺癌是对整个腺体进行系统采样 12 个活检核心，成像时未发现疑似癌症的病灶。目前定性 MR 图像虽然在突出前列腺癌方面大多成功，但看起来可能与 扫描仪到扫描仪，甚至在同一扫描仪上重复。这种可变性增加了复杂性 检测癌症和区分癌症的主观解释过程 有临床意义的惰性疾病。因此，更强大和标准化的 MRI 方法 需要检测和表征具有临床意义的前列腺癌。 该项目计划通过以下具体目标来解决这一问题： (1) 将针对前列腺开发并优化快速高分辨率 3D MRF 采集 通过创新缩小视场成像、3D 笛卡尔采样和 MRF 中的高级重建。提议的 MRF 采集将实现准确的 T1 和 T2 以各向同性亚毫米分辨率 (0.8 mm3) 绘制前列腺图 采集时间小于5分钟。 (2) 使用基于 MRF 的 T1 和 T2 图合成的对比加权图像将取代 用于检测前列腺癌的传统定性图像。 (3) 基于MRF的具有表观扩散系数的T1和T2将被验证用于分离癌症 与非癌症并区分不同级别的癌症。 (4) 来自 MRF 的前列腺癌的微观结构特征将提供以下信息： 亚体素成分（上皮、基质、管腔及其体积分数）以揭示隐匿性 癌症并能够区分不同级别的癌症。 该项目将通过提供可重复和可重复的非侵入性技术来推进前列腺成像 定量成像指标。这些创新将取代传统的对比度加权 使用单一快速高分辨率标准 MRF 协议进行成像，提供客观 前列腺癌的识别和分级，完善前列腺癌的分类 使用微观结构特征，从而减少不必要的活检并促进适当的活检 治疗选择。

Project Summary Abstract The goal is to identify and characterize prostate cancer objectively and accurately using a rapid quantitative Magnetic Resonance Imaging (MRI) approach. The standard-of-care in patients being evaluated for suspicion of prostate cancer is systematic sampling of the entire gland with 12 biopsy cores, without an identified focus suspicious for cancer on imaging. Current qualitative MR images, while mostly successful in highlighting prostate cancer, may look different from scanner to scanner, or even when repeated on the same scanner. This variability adds complexity to an already subjective interpretive process of detecting cancer and discriminating between clinically significant and indolent disease. Thus, more robust and standardized MRI methods to detect and characterize clinically significant prostate cancer are needed. This project plans to address this issue with following specific aims: (1) A rapid high-resolution 3D MRF acquisition will be developed and optimized for prostate cancer assessment by innovating reduced field-of-view imaging, 3D Cartesian sampling, and advanced reconstruction in MRF. The proposal MRF acquisition will enable accurate T1 and T2 mapping over the prostate gland with an isotropic submillimeter resolution (0.8 mm3) in an acquisition time of less than 5 minutes. (2) Contrast-weighted images synthesized using MRF-based T1 and T2 maps will replace conventional qualitative images for detecting prostate cancer. (3) MRF-based T1 and T2 with apparent diffusion coefficient will be validated to separate cancer from non-cancer and differentiate cancers with different grades. (4) Microstructural signatures of prostate cancer derived from MRF will provide information about subvoxel components (epithelium, stroma, lumen, and their volume fractions) to reveal occult cancers and enable the discrimination of different grades of cancer. This project will advance prostate imaging by providing reproducible and repeatable non-invasive quantitative imaging metrics. These innovations will replace conventional contrast-weighted imaging with a single rapid high-resolution standard MRF protocol, provide an objective identification of prostate cancer and grading, and improve the classification of prostate cancer using microstructural signatures, thus reducing unnecessary biopsies and facilitating appropriate treatment selection.